<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366962</url>
  </required_header>
  <id_info>
    <org_study_id>7374-CL-0107</org_study_id>
    <nct_id>NCT02366962</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older</brief_title>
  <official_title>Phase III Study of ASP7374－Open-label Study of Subcutaneous Vaccination of Quadrivalent ASP7374 in Adult Subjects Aged 20 or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMN Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMN Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety until Day 29 after injection of a single
      dose of quadrivalent vaccine ASP7374 in adult subjects aged 20 or older
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by adverse events</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and systemic reactions associated with the vaccination</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Influenza</condition>
  <condition>Vaccine</condition>
  <arm_group>
    <arm_group_label>ASP7374 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASP7374</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>ASP7374 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable, as judged on the basis of history and concurrent diseases

          -  Subject understands procedure of the protocol and is willing to comply with the
             protocol.

        Exclusion Criteria:

          -  Scheduled to receive another vaccine during the study.

          -  Received influenza HA vaccine within 180 days prior to screening.

          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination
             with the study vaccine, and received or scheduled to receive an inactivated vaccine or
             a toxoid within 7 days prior to vaccination with the study vaccine.

          -  Diagnosis of immune deficit in the past has a family member (within the third degree
             of kinship) with a diagnosis of congenital immunodeficiency syndrome.

          -  Received one of the following medications or treatment prior to vaccination with the
             study vaccine:

               -  1. Within 28 days prior to vaccination with the study vaccine

                    1. Interferon formulation

                    2. Drugs which affect the immune system (e.g., immunosuppressants)

                    3. Systemic corticosteroids and inhaled corticosteroids

                    4. G-CSF and M-CSF

               -  2. Within 84 days prior to vaccination with the study vaccine

                    1. Human immunoglobulin products

                    2. Blood products

                    3. Blood transfusion

               -  3. Within 180 days prior to vaccination with the study vaccine

                    1. High-dose human immunoglobulin products (≥200 mg/kg)

          -  History of anaphylactic shock or an allergic reaction such as generalized eruption due
             to food or drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the
             previous vaccination (influenza vaccine and others)

          -  History of seizures (exclude a pyrexial attack in childhood)

          -  History of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM)

          -  Body temperature of ≥37.5°C on Day 1 (before vaccination)

          -  Moderate to severe acute or febrile illness (≥37.5°C) within 7 days prior to
             vaccination

          -  Concurrent hepatic disease (exclude fatty liver, hepatic cyst, biliary stone and
             gallbladder poly, which have laboratory findings only, no clinical symptoms, and not
             necessary to treat), or AST (GOT) and/or ALT (GPT) of &gt;100 IU/L at screening on Day 1

          -  Concurrent renal disease (exclude rental cyst and calculus kidney which have
             laboratory findings only, no clinical symptoms, and not necessary to treat), or
             creatinine of &gt; 1.5 mg/dL at screening

          -  Concurrent respiratory disease, hematologic disease, or developmental disorders

          -  Concurrent or previous heart disease

          -  Concurrent or previous cerebrovascular disorder

          -  Concurrent malignancy or diagnosis or treatment of malignancy within 5 years before
             screening

          -  Diagnosis of mental disorder including schizophrenia, bipolar disorder, or major
             depressive disorder or cognitive impairment, or received medications for cognitive
             impairment

          -  Concurrent disease interfering with the evaluation of local and systemic reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>ASP7374</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

